TO THE EDITOR
Allogeneic stem cell transplantation may hold the potential of curing multiple myeloma (MM). Despite high treatment-related mortality of 17-40%, 1 lower relapse rates in comparison to autologous transplantation have been reported, probably due to a graft-versus-myeloma effect exerted by immunocompetent donor lymphocytes.
Reduced intensity conditioning (RIC) allografts, using nonmyeloablative regimens, have been successfully undertaken in a variety of hematological malignancies including myeloma. They permit the reduction of treatment-related mortality while laying the platform for adoptive immunotherapy based on donor lymphocyte infusion (DLI). 2, 3 DLI has, in the last decade, been shown to be a powerful weapon in the treatment of relapsed or persistent malignant diseases following allogeneic stem cell transplantation as reported for leukemia and myeloma [4] [5] [6] among other diseases. The optimal dose, timing and eventual escalation strategy for DLI still remain to be defined and may vary from disease to disease. A high T-cell dose of more than 1 Â 10 8 T cells/kg has been shown to correlate with response in myeloma patients. 5 However, considering the relatively high incidence of graftversus host disease (GvHD) observed in these previous studies, we sought to use an escalation strategy with a low initial T-cell dose. The concept of using an escalating dose of DLI instead of a single high dose has been successfully evaluated by Mackinnon et al 7 and Dazzi et al. 8 Here, we report on the toxicity and efficacy of low-dose DLI for persistent, progressive or relapsed myeloma following RIC allografting.
In all, 21 patients were treated at five BMT centers using a melphalan/fludarabine-based dose-reduced conditioning followed by allograft from related or unrelated donor. The studies were approved by the local ethic committee of each participating center.
Donor lymphocytes were given only if no active GvHD, no severe organ impairment and no severe infections were present in the patient.
The eligibility criteria for DLI were as follows:
1. asymptomatic persistence of paraprotein in serum or positive immunofixation in blood or 410% plasma cells in the bone marrow not before day 120 after transplantation and withdrawal of all immunosuppressive therapy for at least 3 weeks, or 2. progression or relapse after complete remission (CR) at any time after transplantation, but after at least 3 weeks after withdrawal of immunosuppressive therapy.
The initial dose of T cells was 1 Â 10 6 CD3 þ cells/kg for unrelated and 5 Â 10 6 CD3 þ cells /kg for HLA-identical sibling DLI.
If no response or GvHD was seen 3 months after the first DLI, a dose escalation was carried out with 5 Â 10 6 CD3 þ cells/kg for unrelated and 1 Â 10 7 CD3 þ cells/kg for related stem cell transplantation. The second DLI could be administered before the 3 months' interval in case of progressive disease. If no response or GvHD were seen after the second DLI, a further log escalation was recommended, but further treatment was up to the participating center.
The patients' characteristics are summarized in Table 1 . All patients had undergone conditioning with fludarabine (90-180 mg/m 2 ) and melphalan (100-150 mg/m 2 ). In all, 18 patients had received antithymocyte globulin (anti-rabbit, Fresenius, Bad Homburg, Germany) (10-60 mg/kg body weight (BW)). Further GvHD prophylaxis consisted of cyclosporin A and short-course methotrexate. The DLIs were received from a related donor (n ¼ 11) or an unrelated donor (n ¼ 10). Of the patients, 12 had experienced GvHD prior to DLI ( Table 1 ). The median interval between stem cell transplantation and first DLI was 211 days (range, 111-610). The median dose for initial DLI was 1.0 Â 10 6
CD3
þ cells/kg BW for unrelated donor and 4.7 Â 10 6 CD3 þ cells/kg BW for sibling donors. Patients 11 and 17 had each received only 1 Â 10 6 CD3 þ cells/kg from HLA-identical sibling due to limited availability at the time of DLI.
Dose escalation was dependent on disease response and on the development of acute GvHD (aGvHD) or chronic GvHD (cGvHD) . Nine patients received a second DLI after a median of 91 days (range, 29-270). Three patients received a third and one patient a fourth DLI procedure. Five patients received concomitant treatment with thalidomide (n ¼ 2), interferon alpha (n ¼ 2) or local radiotherapy (n ¼ 1) either because of failure to first or second DLI (n ¼ 3), rapid progression (n ¼ 1) or extramedullary disease (n ¼ 1).
Response to treatment was defined according to the criteria set by the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplantation Registry (IBMTR). DLI-induced cytopenia was defined as the occurrence of an absolute WBC count of less than 1.0 Â 10 9 /l and/or a platelet count less than 20 Â 10x 9 /l not due to prior or concomitant treatment or disease. Overall survival was calculated from transplantation until death from any cause.
Results

Toxicity
No cytopenia was observed in any patient after DLI. All 21 patients were evaluated for GvHD. Four patients (19%) developed grade I aGvHD and three patients grade II-IV aGvHD (14%). One patient died of severe grade IV aGvHD. In 16 patients no signs of cGvHD were seen, while in six patients (29%) cGvHD was seen, which was limited (n ¼ 5) or extensive (n ¼ 1). Despite the lower median cell dose for unrelated DLI (first DLI unrelated donors: 1 Â 10 6 CD3 þ cells/kg vs 4.7 Â 10 6 CD3 þ cells/kg for related donors), the incidence of acute grade II-IV GvHD was higher than after DLI Correspondence from HLA-identical siblings (30 vs 0%; NS). We could not establish a relation between prior aGvHD and the development or severity of GvHD after DLI. Neither could we establish a relationship between the maximum T-cell dose administered and development of aGvHD or cGvHD (data not shown).
Response
All patients are evaluable for clinical response. Eight patients (38%) showed a clinical response with CR (n ¼ 4; 19%) and partial remission (PR) (n ¼ 4; 19%). Six patients (29%) remained in stable disease, while seven patients (33%) experienced progressive disease. Only one patient showed response (CR) without any signs of aGvHD or cGvHD. Four other patients responded with only grade I aGvHD or limited cGvHD. The median DLI dose that led to response was 1.0 Â 10 6 CD3 þ cells/kg BW. The median time to response was 64 days (range, 21-432). Six out of 21 patients (29%) responded after the first DLI and two of nine (22%) after the second infusion. No patients responded to the third (n ¼ 3) or fourth (n ¼ 1) DLI procedure ( Table 2) . Four of 10 patients (40%) showed response after MUD-DLI (all PR), while four of 11 (36%) responded after MRD-DLI (CR: 27%; PR: 9%). One patient died of grade IV aGvHD after DLI and five patients died of progressive disease after DLI. After a median follow-up of 520 days (range, 218-939) after stem cell transplantation and 221 days (range, 111-601) after DLI, 71% of the patients are alive, with three patients still in CR, lasting now 8, 13 and 14 months, respectively. Three patients with progressive disease after DLI are now in PR after treatment with thalidomide (n ¼ 2) and retransplantation with melphalan, respectively. Five patients still have stable disease (3-13 months, after DLI), two of them with normal serum immunoglobulin levels but persistent positive immunofixation (Table 1) .
Discussion
Standard myeloablative allogeneic stem cell transplantation for myeloma is associated with a rather high treatment-related mortality. We and others have shown that RIC allows stable engraftment of allogeneic stem cells in myeloma patients while reducing treatment-related mortality and laying the foundation for further adoptive immunotherapy with DLI. Owing to the limited antitumour effect of most RIC regimens, DLI are often an integral part of the treatment strategy. The existence of a graftversus-myeloma effect has so far been shown in several reports particularly after HLA-identical transplantation. 5, 6 Most studies till date have used relatively high T-cell doses, resulting in a high rate of aGvHD up to 55%. 5 The high incidence of GvHD has so far been a limitation of this rather promising strategy. We thus considered it important to find DLI doses that may induce a graft-versus-myeloma effect without GvHD. In this study, we demonstrate marked graft-versus-myeloma effect in patients with persistent, progressive or relapsed disease. The overall response rate of (38%) with relatively low toxicity (14% grade II-IV aGvHD, 5% extensive cGvHD) and no cytopenia in both the MRD and MUD allografts may be attributed to our escalation strategy with relatively low starting doses (1.0 Â 10 6
CD3
þ /kg BW for unrelated grafts and 4.7 Â 10 6 CD3 þ /kg BW for sibling grafts). Indeed, five of eight responders only experienced grade I aGvHD, limited cGvHD or no GvHD at all. No patient developed grade II-IV aGvHD after MRD-DLI, while three patients experienced grade II-IV GvHD after MUD-DLI, despite the lower T-cell dose.
In a recent report, a T-cell dose of more than 1 Â 10 8 cells/kg BW showed the highest correlation with response to DLI. 5 In a recent multicenter study including various hematological diseases, the median DLI dose that resulted in a complete response was 1 Â 10 7 CD3 þ /kg BW. 9 In this report, however, no CR and only one PR was seen in 10 patients with myeloma. In our study, the median DLI dose that led to response was 1.0 Â 10 6 CD3 þ cells/kg BW. Indeed, seven of eight responders (86%) had received less than or equal 1 Â 10 7 CD3 þ /kg BW. Response was observed after the first (29%) or second (22%) DLI, while none of the patients responded after the third or fourth DLI. The number of patients who received more than two DLI is rather small to draw any conclusions.
Our data show that it is possible to achieve remission in myeloma patients who have relapsed, persistent or progressive disease following RIC allografting with much lower T-cell numbers than has so far been published. The incidence and severity of aGvHD and cGvHD was relatively low. Despite the lower number of T cells administered from unrelated donors, the probability of aGvHD seems higher, indicating the need for a further reduction of the first DLI dose as is prescribed in our current protocol (5 Â 10 5 CD3 þ cells/kg BW). Our approach with escalating T cells may be particularly applicable in patients with residual disease in an attempt to achieve CRs at relatively low risk of severe GvHD.
